Guillaume Bossis

14PUBLICATIONS
55CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsProcess control and simulationPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 15, 2025
Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.

Rawan Hallal, Marion de Toledo, Denis Tempé

|Jul 19, 2024
Generation of non-genetically modified, CAR-like, NK cells.

Loïs Coënon, Emilie Rigal, Hortense Courot

|Jul 18, 2023
DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias.

Mathias Boulanger, Mays Aqrouq, Denis Tempé

|Dec 21, 2022
Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice.

Damien Dufour, Typhanie Dumontet, Isabelle Sahut-Barnola

|Jul 29, 2022
TRIM28-dependent SUMOylation protects the adult ovary from activation of the testicular pathway.

Moïra Rossitto, Stephanie Déjardin, Chris M Rands

|Apr 22, 2022
Trim39 regulates neuronal apoptosis by acting as a SUMO-targeted E3 ubiquitin-ligase for the transcription factor NFATc3.

Meenakshi Basu-Shrivastava, Barbara Mojsa, Stéphan Mora

Pageof 3

Frequent Collaborators

3 joint publications

Mathias Boulanger

3 joint publications

Marion de Toledo

2 joint publications

Marc Piechaczyk

2 joint publications

Martin Villalba